Stockscreener 앱 받기
91.07
0.32%
0.29
시간 외 거래:
90.75
-0.32
-0.35%
전일 마감가:
$90.78
열려 있는:
$91.75
하루 거래량:
11.88M
Relative Volume:
0.95
시가총액:
$158.63B
수익:
$45.13B
순이익/손실:
$6.28B
주가수익비율:
25.37
EPS:
3.5895
순현금흐름:
$7.38B
1주 성능:
+6.39%
1개월 성능:
+4.47%
6개월 성능:
-27.19%
1년 성능:
-32.01%
1일 변동 폭
$90.95
$92.73
1주일 범위
$85.60
$92.73
52주 변동 폭
$81.97
$139.06
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
91.07 | 158.12B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.66 | 115.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
81.67 | 105.19B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
48.55 | 72.61B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.96 | 50.35B | 6.30B | 1.07B | 1.09B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott Laboratories (ABT) Is Up 6.4% After European Approval of Dual Glucose‑Ketone Sensors - simplywall.st
Abbott studies reinforce DKA opportunity following dual sensor milestone - Drug Delivery Business
Abbott reports rising DKA hospitalizations among diabetics - Investing.com
Kids’ diabetes hospital stays now mostly from ketoacidosis, Abbott finds - Stock Titan
Abbott Laboratories slammed on its post-Exact Sciences guidance - MSN
Abbott Says Timing Mismatch Lets $8B Gain Go Untaxed - Law360
What is Abbott Tokenized Stock (Ondo)(ABTON) Coin? A comprehensive guide you shouldn’t miss - WEEX
A Grandma Bought PediaSure To Help Her Grandson Grow — Now, Abbott Is In Federal Court - Benzinga
A Grandma Bought PediaSure To Help Her Grandson Grow — Now, Abbott Is In Federal Court - Benzinga
Abbott Laboratories stock is getting decimated, but the smart money senses opportunity - MSN
Better medical device stock right now: Abbott Laboratories vs. Dexcom - MSN
Is It Too Late to Buy Abbott Laboratories (ABT) After 4.4% Rally? GF Value Says Undervalued - GuruFocus
Judge Questions Fees In Abbott Investors' $40M Formula Deal - Law360
Abbott Can’t Drop PediaSure Children’s Growth Deception Suit - Bloomberg Law News
Abbott Labs must face lawsuit over PediaSure children's growth claims - Reuters
Abbott Labs must face lawsuit over PediaSure children’s growth claims - The Mighty 790 KFGO
Abbott Laboratories Stock (ABT) Closed Up by 4.18% on Jun 4: Drivers Behind the Movement - TradingKey
Abbott Laboratories stock (US0028241000): shares advance on strong US trading - AD HOC NEWS
[Latest] Non-Invasive Blood Glucose Monitoring Devices Market Size to Hit USD 340.49 Million with a Promising CAGR of 25.60% by 2034 - GlobeNewswire Inc.
Abbott Laboratories stock gains as Norges Bank acquires new institutional position - Traders Union
Abbott Laboratories shares jump as stock buying pressure builds - Traders Union
Abbott shares rise as investors refocus on diabetes tech and cancer-diagnostics momentum - Quiver Quantitative
Abbott Laboratories on Pace for Largest Percent Increase Since April 2023 -- Data Talk - Moomoo
Abbott Addresses a Major Diabetes Care Gap With Tech Innovation - Yahoo Finance
Jim Cramer Says “No One Disputes the Science and Commercial Smarts of Abbott” - Insider Monkey
Abbott Pakistan’s profit surge masks a volume problem - Profit by Pakistan Today
Assessing Abbott Laboratories (ABT) Valuation After New Diabetes Sensor And Cancer Screening Tailwinds - Yahoo Finance
Abbott Laboratories stock (US0028241000): U.S. healthcare name steadies after recent slide as instit - AD HOC NEWS
MiniMed expands Abbott partnership to add dual glucose-ketone sensor - MedTech Dive
Is Abbott Laboratories stock underperforming the Dow? - MSN
MiniMed Shares Rise on 4Q Sales, Abbott Partnership Expansion - marketscreener.com
Abbott (ABT) Expands Collaboration with MiniMed for Innovative G - GuruFocus
MiniMed partners with Abbott on dual glucose-ketone sensors By Investing.com - Investing.com Canada
Abbott Laboratories Deadline Alert - TMX Newsfile
Abbott India Ltd. Faces Bearish Momentum Amid Technical Downgrade - Markets Mojo
How A Steady Valuation Is Shaping The Evolving Abbott Laboratories (ABT) Investment Story - Yahoo Finance
Abbott Laboratories stock (US0028241000): shares edge higher ahead of Q2 2026 earnings after guidanc - AD HOC NEWS
Is Abbott Laboratories (ABT) Now Attractive After A 33% One Year Share Price Slide - simplywall.st
Why Investors Are Cautious on Abbott Laboratories (ABT) - Insider Monkey
Why Investors Are Cautious on Abbott Laboratories (ABT)? - Yahoo Finance
The demand for healthcare is going to continue to accelerate, says Abbott Labs CEO Robert Ford - MSN
ASCO26: Abbott demonstrates MRD test benefit in TNBC recurrence - Medical Device Network
Peripheral Vascular Devices Market by Type, End User - GlobeNewswire Inc.
Abbott Labs Spinal Cord Device Causes Shocks, Suit Claims - Law360
Tax Havens Cost US $40 Billion After Trump Withdraws From Global Deal - The Fiscal Times
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Goldman Sachs Maintains Abbott Laboratories(ABT.US) With Buy Rating, Cuts Target Price to $113 - Moomoo
Abbott Laboratories stock (US0028241000): shares steady after CE mark win for Libre Duo system - AD HOC NEWS
Precision Trading with Abbott Laboratories (ABT) Risk Zones - Stock Traders Daily
Abbott's CE Mark Win for Libre Duo Systems May Lift Its Stock - Yahoo Finance Australia
Ophthalmology Devices Market Is Going to Boom | Abbott Laboratories, Carl Zeiss AG, CooperVision - openPR.com
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
애보트 래버러토리스 주식 (ABT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| STARKS DANIEL J | Director |
Apr 27 '26 |
Buy |
92.65 |
10,000 |
926,537 |
6,751,103 |
1.48%
0.32%
자본화:
|
볼륨(24시간):